Diabetes

  • In reply: How should diabetic dyslipidemia be treated?
    Ting-I Lee, MD, PhD
    Cleveland Clinic Journal of Medicine January 2020, 87 (1) 11; DOI: https://doi.org/10.3949/ccjm.87c.01004
  • How should diabetic dyslipidemia be treated?
    Taher Modarressi, MD
    Cleveland Clinic Journal of Medicine January 2020, 87 (1) 11; DOI: https://doi.org/10.3949/ccjm.87c.01003
  • In reply: Is diabetes still a compelling indication for renin-angiotensin-aldosterone system inhibitors?
    Sunil Bhandari, MBChB, FRCP, PhD, M Clin Edu, FHEA, Tasnim Momoniat, MBChB, MRCP (UK) and Duha Ilyas, MBBS, MRCP (UK)
    Cleveland Clinic Journal of Medicine January 2020, 87 (1) 9-10; DOI: https://doi.org/10.3949/ccjm.87c.01002
  • Is diabetes still a compelling indication for renin-angiotensin-aldosterone system inhibitors?
    Robert Fakheri, MD, Sripal Bangalore, MD and Franz Messerli, MD
    Cleveland Clinic Journal of Medicine January 2020, 87 (1) 9; DOI: https://doi.org/10.3949/ccjm.87c.01001
  • Diabetes management
    Cleveland Clinic Journal of Medicine November 2019, 86 (11) 760;

    Information was omitted from Table 1 on page 596 of the article, Makin V, Lansang MC. Diabetes management: Beyond hemoglobin A1c. Cleve Clin J Med 2019; 86(9):595–600. doi:10.3949/ccjm.86a.18031

  • Clinical outcomes in diabetes: It’s not just the glucose (and it’s not so simple)
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine September 2019, 86 (9) 573-574; DOI: https://doi.org/10.3949/ccjm.86b.09019

    As we dig deeper into the reduction in cardiovascular deaths seen with some newer drugs, several questions arise.

  • Diabetic dyslipidemia with eruptive xanthoma
    Yu-Chun Hsueh, MD, Chuan-Liang Chou, MD and Ting-I. Lee, MD, PhD
    Cleveland Clinic Journal of Medicine September 2019, 86 (9) 575-576; DOI: https://doi.org/10.3949/ccjm.86a.18104

    Off medications for 1 year, her triglyceride level was 10,250 mg/dL, hemoglobin A1c 12.4%.

  • Diabetes management: Beyond hemoglobin A1c
    Vinni Makin, MBBS, MD, FACE and M. Cecilia Lansang, MD, MPH
    Cleveland Clinic Journal of Medicine September 2019, 86 (9) 595-600; DOI: https://doi.org/10.3949/ccjm.86a.18031

    Other factors include cardiovascular benefit, weight control, hypoglycemia risk, and cost.

  • Gastroparesis
    Amos Lal, MD, Pantea Ebrahimpour, MD and Nitin Trivedi, MD, FACP, FACE
    Cleveland Clinic Journal of Medicine August 2019, 86 (8) 514; DOI: https://doi.org/10.3949/ccjm.86c.08001

    A reader raises questions about diabetic gastroparesis (April 2019).

  • In reply: Gastroparesis
    Ahmad Muneer Sharayah, MD, Noor Hajjaj, MD, Ramy Osman, MD and Douglas Livornese, MD
    Cleveland Clinic Journal of Medicine August 2019, 86 (8) 514; DOI: https://doi.org/10.3949/ccjm.86c.08002

Pages